MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
卡托普利对 BMT 后肺损伤的调节
基本信息
- 批准号:2551560
- 负责人:
- 金额:$ 7.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2000-06-30
- 项目状态:已结题
- 来源:
- 关键词:DNA footprinting barbiturates biomarker bone marrow transplantation captopril chemoprevention clinical research clinical trials ferritin guanosine human subject iron metabolism leukocytes lipid peroxides pulmonary fibrosis /granuloma respiratory function transferrin transforming growth factors transplantation immunology
项目摘要
DESCRIPTION (Applicant's Description)
The objective of this proposal is to understand, in a clinical laboratory
translational trial, the pathophysiology of lung injury associated with
high-dose chemoradiotherapy followed by BMT. The observation that
interstitial pneumonia syndrome (IPS) is associated with autologous and
allogeneic transplantation suggests that multiple processes act in concert
to initiate the process that leads to IPS. We have observed a striking and
consistent elevation in serum iron levels and saturation of transferrin in
patients undergoing BMT. These data suggest that a temporary state of
iron-overload occurs, and that this is accompanied by the generation of
iron-catalyzed reactive oxygen species (ROS). We hypothesize that these ROS
cause lung damage after BMT either by causing direct damage to lung cells,
or by activating an inflammatory cascade that contributes to lung injury.
In order to test the hypothesis we propose the following specific aims: (1)
To determine, in a clinical trial, if the thiol anti-oxidant/iron chelator
captopril can prevent lung injury after high-dose chemotherapy/radiotherapy
or chemotherapy alone in patients undergoing bone marrow transplantation
(BMT). Measures of lung injury include (a) high-resolution CT-scans, (b)
measures of lung function (FEV, FVC, DLCO, pulse oximetry). (2) To
establish surrogate markers of oxidant-mediated lung injury in serum and DNA
from peripheral blood white cells in patients undergoing BMT. We will
measure (a) footprints of oxidant-mediated injury to (1) cellular DNA
(8-hydroxyguanosine (8-OHDGI), and (2) cellular membranes and cytoplasm (a)
aldehydes, lipid hydroperioxides and thiobarbituric acid reactive substances
(TBARS) and (b) inflammatory mediators and growth factors, including TGF-P.
Measures of iron will include a)serum free iron, (b) serum iron, (c)
transferrin and (d) ferritin samples will be collected at various times
during and after BMT.
To accomplish these aims we have assembled a multidisciplinary team of
investigators with experience in clinical BMT assessment of lung injury, the
biology of inflammation and free radical biology. The results obtained from
these studies will provide new information on the mechanisms of IPS after
BMT and should have important implications for patient, who undergo BMT.
申请人的描述(Applicant's Description)
本提案的目的是了解,在临床实验室中,
翻译试验,肺损伤的病理生理学与
大剂量放化疗后进行骨髓移植 的观察结果
间质性肺炎综合征(IPS)与自体和
同种异体移植表明多个过程协同作用,
启动导致IPS的过程。 我们观察到一个惊人的,
血清铁水平和转铁蛋白饱和度持续升高,
接受BMT的患者。 这些数据表明,
铁超载发生,这是伴随着产生的
铁催化活性氧(ROS)。 我们假设这些活性氧
通过直接损伤肺细胞,
或者通过激活导致肺损伤的炎症级联反应。
为了验证这一假设,我们提出了以下具体目标:(1)
在临床试验中,确定巯基抗氧化剂/铁螯合剂
卡托普利可预防大剂量化疗/放疗后肺损伤
或单纯化疗,
(BMT)。 肺损伤的测量包括(a)高分辨率CT扫描,(B)
肺功能指标(FEV、FVC、DLCO、脉搏血氧饱和度)。 (2)到
建立血清和DNA中氧化剂介导肺损伤替代标志物
从接受BMT的患者的外周血白色细胞中。 我们将
测量(a)氧化剂介导的损伤对(1)细胞DNA的足迹
(2)细胞膜和细胞质(a)
醛、脂质过氧化氢和硫代巴比妥酸反应物质
(TBARS)和(B)炎性介质和生长因子,包括TGF-β。
铁的测量将包括a)血清游离铁,(B)血清铁,(c)
转铁蛋白和(d)铁蛋白样本将在不同时间采集
在BMT期间和之后。
为了实现这些目标,我们组建了一个多学科团队,
具有临床BMT肺损伤评估经验的研究者,
炎症生物学和自由基生物学 获得的结果
这些研究将为IPS的机制提供新的信息,
BMT和应该有重要意义的病人,谁接受BMT。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leo I. Gordon其他文献
Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma
- DOI:
10.1182/blood-2022-158864 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Jonathan Scott Rink;Stephen E. Henrich;Alexandra Moxley;Xu Hannah Zhang;Xiwei Wu;SonBinh Nguyen;Christiane Querfeld;David A. Horne;Steve T. Rosen;Leo I. Gordon;Colby Shad Thaxton;Adam Yuh Lin - 通讯作者:
Adam Yuh Lin
A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL
- DOI:
10.1182/blood-2023-185065 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Oluwatobi Odetola;Shuo Ma;Jane N. Winter;Barbara Pro;Ishan Roy;Ping Xie;Bin Zhang;George Koulogeorgas;Xinlei Mi;Robert Bayer;Robert Eisner;Valerie Nelson;Habib Shaikh;Dean Tsarwhas;Faisal Saghir;Parameswaran Venugopal;Leo I. Gordon;Reem Karmali - 通讯作者:
Reem Karmali
Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
癌症和药物相关的血栓性血小板减少性紫癜和溶血性尿毒症综合征。
- DOI:
- 发表时间:
1997 - 期刊:
- 影响因子:0
- 作者:
Leo I. Gordon;H. Kwaan - 通讯作者:
H. Kwaan
Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL
- DOI:
10.1182/blood-2023-180014 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Michael L. Wang;Leo I. Gordon;Alexandre V Hirayama;Matthew A Lunning;Ling Shi;Shien Guo;Ana Kostic;Laurie Eliason;Jinender Kumar;Maria Lia Palomba - 通讯作者:
Maria Lia Palomba
Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis
- DOI:
10.1182/blood-2022-167872 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Megan Melody;Madelyn Burkart;Marcelo Villa;Fenlu Zhu;Jane N. Winter;Reem Karmali;Adam Yuh Lin;Leo I. Gordon;Kehinde Adekola;Jonathan Moreira;Seema Singhal;Jayesh Mehta - 通讯作者:
Jayesh Mehta
Leo I. Gordon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leo I. Gordon', 18)}}的其他基金
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
IDEC Y2B8 放射免疫疗法与 Rituxan 治疗复发 B 细胞淋巴瘤的比较
- 批准号:
6304166 - 财政年份:1999
- 资助金额:
$ 7.4万 - 项目类别:
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
IDEC Y2B8 放射免疫治疗 B 细胞非霍奇金淋巴瘤
- 批准号:
6304157 - 财政年份:1999
- 资助金额:
$ 7.4万 - 项目类别:
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
利妥昔单抗治疗后的 IDEC Y2B8 放射免疫治疗非霍奇金淋巴瘤
- 批准号:
6304161 - 财政年份:1999
- 资助金额:
$ 7.4万 - 项目类别:
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
IDEC 10603--IDEC Y2B8 用于 B 细胞淋巴瘤患者
- 批准号:
6114067 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
利妥昔单抗治疗后的 IDEC Y2B8 放射免疫治疗非霍奇金淋巴瘤
- 批准号:
6263971 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
IDEC Y2B8 放射免疫治疗 B 细胞非霍奇金淋巴瘤
- 批准号:
6263967 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
IDEC Y2B8 放射免疫疗法与 Rituxan 治疗复发 B 细胞淋巴瘤的比较
- 批准号:
6263976 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
卡托普利对 BMT 后肺损伤的调节
- 批准号:
2896367 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
IDEC 106-03--PHASE I/II CLINICAL TRIAL TO EVALUATE IDEC-Y2B8
IDEC 106-03--评估 IDEC-Y2B8 的 I/II 期临床试验
- 批准号:
6245190 - 财政年份:1997
- 资助金额:
$ 7.4万 - 项目类别:
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
IDEC 10603--IDEC Y2B8 用于 B 细胞淋巴瘤患者
- 批准号:
6275302 - 财政年份:1997
- 资助金额:
$ 7.4万 - 项目类别:
相似海外基金
MOLECULAR MECHANISMS OF BARBITURATES AT GABA-A RECEPTORS
巴比妥类药物在 GABA-A 受体上的分子机制
- 批准号:
6186427 - 财政年份:2000
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR MECHANISMS OF BARBITURATES AT GABA-A RECEPTORS
巴比妥类药物在 GABA-A 受体上的分子机制
- 批准号:
2889982 - 财政年份:1999
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR MECHANISMS OF BARBITURATES AT GABA-A RECEPTORS
巴比妥类药物在 GABA-A 受体上的分子机制
- 批准号:
2674540 - 财政年份:1998
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR MECHANISMS OF BARBITURATES AT GABA-A RECEPTORS
巴比妥类药物在 GABA-A 受体上的分子机制
- 批准号:
2460299 - 财政年份:1997
- 资助金额:
$ 7.4万 - 项目类别:
MOLECULAR MECHANISMS OF BARBITURATES AT GABA-A RECEPTORS
巴比妥类药物在 GABA-A 受体上的分子机制
- 批准号:
2242968 - 财政年份:1997
- 资助金额:
$ 7.4万 - 项目类别:
ACUTE AND CHRONIC BARBITURATES--IN VITRO BIOCHEMISTRY
急性和慢性巴比妥酸盐——体外生物化学
- 批准号:
2118213 - 财政年份:1990
- 资助金额:
$ 7.4万 - 项目类别: